Darlifarnib Plus Cabozantinib Is Active in ccRCC After Prior CabozantinibByJason M. BroderickApril 17th 2026
IO/TKI Combinations Shift the Standard of Care in Renal Cell CarcinomaByTargeted Oncology StaffApril 13th 2026